Sep 18, Further improvements in the treatment of NSCLC can only be achieved with continued development of novel targeted approaches and correlative science studies that will help select proper patients for various treatment strategies. Efficacy of various doublet chemotherapy combinations. In recent years, several randomized trials comparing various doublet chemotherapy combinations have determined that efficacy is similar between most of the regimens Table 1. Results indicate that chemotherapy doublets should not be withheld in elderly patients solely on the basis of age.
|Published (Last):||8 December 2007|
|PDF File Size:||16.95 Mb|
|ePub File Size:||20.46 Mb|
|Price:||Free* [*Free Regsitration Required]|
Send email Cancel. Add to Collections Create a new collection Add to an existing collection. Name your collection: Name must be less than characters. Choose a collection: Unable to load your collection due to an error Please try again.
Add Cancel. Add to My Bibliography My Bibliography. Unable to load your delegates due to an error Please try again. Your saved search Name of saved search:. Search terms:. Test search terms. Would you like email updates of new search results? Email: change. Frequency: Monthly Weekly Daily.
Which day? Send at most: 1 item 5 items 10 items 20 items 50 items items items. Send even when there aren't any new results. Optional text in email:. Save Cancel. Create a file for external citation management software Create file Cancel.
Full-text links Cite Favorites. Similar articles Cost-minimization analysis for Portugal of five doublet chemotherapy regimens from two phase III trials in the treatment of advanced non-small cell lung cancer.
Pimentel FL, et al. Lung Cancer. Epub May 2. PMID: A model to select regimens for phase III trials for patients with advanced-stage non-small cell lung cancer. Freidlin B, et al. Clin Cancer Res. Hainsworth JD, et al. J Clin Oncol. Docetaxel in combination with platinums in patients with advanced non-small-cell lung cancer. Belani CP. Oncology Williston Park. PMID: Review. Docetaxel in the treatment of non-small cell lung cancer: review of single-agent trials. Fossella FV.
Semin Oncol. Show more similar articles See all similar articles. Cited by 18 articles Risk factors of acquired TM mutation in patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer. Ouyang W, et al. J Cancer. Sun S, et al. Zhongguo Fei Ai Za Zhi. Sequence-dependent synergistic cytotoxicity of icotinib and pemetrexed in human lung cancer cell lines in vitro and in vivo.
Liu T, et al. J Exp Clin Cancer Res. Comprehensive treatment with Chinese medicine in patients with advanced non-small cell lung cancer: A multicenter, prospective, cohort study.
Liu J, et al. Chin J Integr Med. Epub Oct Expression of the copper transporters hCtr1, ATP7A and ATP7B is associated with the response to chemotherapy and survival time in patients with resected non-small cell lung cancer.
Yang T, et al. Oncol Lett. Epub Jul Show more "Cited by" articles See all "Cited by" articles. Full-text links [x] Elsevier Science. Copy Download.
Advanced (NSCLC): Implications from Recent Trials
Study record managers: refer to the Data Element Definitions if submitting registration or results information. This is a Phase III, open label, randomized study to enroll patients with advanced in a ratio at the time of registration. For the purpose of the study, treatment Arm A or Arm B will consist of up to four cycles of therapy repeated every 21 days. Primary endpoint of the study is overall survival; secondary endpoints include toxicity, response rate, and progression-free survival.